GlassScriptPhysician profile
Charles A Mitgang
NPI 1114923315
$26,442.32
in general payments reported to CMS, 2019-2025
69 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,735 · 2020: $2,793 · 2021: $4,456 · 2022: $4,456 · 2023: $3,602 · 2024: $3,801 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,902.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,017.06 | 2019-2025 | |
| Novo Nordisk INC | $2,403.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,266.82 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,111.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $2,035.60 | 2019-2025 | |
| Lilly USA, LLC | $1,131.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $927.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $901.25 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Genzyme Corporation | $867.89 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $819.80 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $800.77 | 2019-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $748.15 | 2020-2023 | |
| Amarin Pharma, INC. | $734.86 | 2019-2023 | |
| Allergan, INC. | $693.52 | 2019-2020 | |
| Esperion Therapeutics, INC. | $640.41 | 2020-2024 | Nexletol, Nexlizet |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mitgang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.